Fig. 1: MW05 and MW07 disrupting the interaction of SARS-CoV-2 RBD with hACE2 receptor. | Nature Communications

Fig. 1: MW05 and MW07 disrupting the interaction of SARS-CoV-2 RBD with hACE2 receptor.

From: Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys

Fig. 1: MW05 and MW07 disrupting the interaction of SARS-CoV-2 RBD with hACE2 receptor.The alternative text for this image may have been generated using AI.

a The binding abilities of MW05 and MW07 to SARS-CoV-2 RBD recombinant protein were assessed by ELISA. b, c The abilities of MW05 and MW07 to block SARS-CoV-2 RBD interaction with ACE2 were evaluated by competition ELISA. d The binding of MW05 and MW07 to SARS-CoV-2 S protein expressed on HEK293 cells was measured by FACS. e The dissociation constants (Kd) of MW05 and MW07 to SARS-CoV-2 S1 recombinant protein were measured using a BIAcore S200 system. f The cross-reactivities of MW05 and MW07 to SARS-CoV-CoV-2, SARS-CoV, and MERS-CoV recombinant S1 subunit of spike proteins (S1) were tested by ELISA. g The binding of MW05 and MW07 to RBD recombinant proteins of SARS-CoV-2-mutated strains.

Back to article page